CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer

Who could benefit from this research

What this research studies

This study investigates whether combining a CXCR1/2 inhibitor (SX-682) with enzalutamide can extend benefits for men whose metastatic castration-resistant prostate cancer has progressed after abiraterone therapy. It uses a single-arm design to evaluate safety and preliminary effectiveness in the target population. Participants would receive the oral SX-682 alongside ongoing enzalutamide, with regular monitoring for responses and adverse events. The goal is to find a treatment option that works differently from current AR-targeted therapies to delay disease progression and improve survival. Results could inform future trials and potential new standards of care for this patient group.

Why it matters

Where this research is happening

• Syntrix Biosystems, INC.
  Auburn, United States Active

Researchers

• Principal investigator: Schuler, Aaron D — Syntrix Biosystems, INC.
• Study coordinator: Schuler, Aaron D

Related research

Other NIH-funded projects on the same topics.

• Hyperactive methylation in a hard-to-treat prostate cancer subtype

  Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11415138

• A newly discovered heavily methylated form of advanced prostate cancer

  Researchers are looking at a newly found heavily methylated type of advanced prostate cancer to find markers and possible weak points for treatment in men with metastatic castration‑resistant prostate cancer.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11181255

• A new treatment for advanced prostate cancer that has stopped responding to abiraterone.

  This research is testing a new combination of medicines, SX-682 and enzalutamide, for men whose advanced prostate cancer has become resistant to abiraterone.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-11114019

• Investigating a new treatment for men with advanced prostate cancer resistant to standard therapies

  This study is looking for men with advanced prostate cancer who haven't had success with common treatments to see if a new drug called SX-682, when combined with enzalutamide, can help improve their treatment results.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-10884438

• Understanding how aggressive cell states emerge in castration-resistant prostate cancer

  A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.

  NIH research State University New York Stony Brook · Stony Brook, United States · NIH-11463275

• Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer

  Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.

  NIH research University of Maryland Baltimore · Baltimore, United States · NIH-11452128

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.